Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same

Abstract

The present invention is directed to methods and compositions for treating and ameliorating AAMI, hippocampal dysfunction, memory disorders, and brain damage, comprising a composition comprising uridine, an acyl derivative thereof, or a uridine phosphate.

1 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of Age-Associated Memory Impairment (AAMI) in a subject. 
   
   
       2 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of Age-Associated Memory Impairment (AAMI) in a subject. 
   
   
       3 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a post-traumatic stress disorder in a subject. 
   
   
       4 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a post-traumatic stress disorder in a subject. 
   
   
       5 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a stress-induced memory disorder in a subject. 
   
   
       6 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a stress-induced memory disorder in a subject. 
   
   
       7 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a depression-induced memory disorder in a subject. 
   
   
       8 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of a depression-induced memory disorder in a subject. 
   
   
       9 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with an autism-spectrum disorder. 
   
   
       10 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with an autism-spectrum disorder. 
   
   
       11 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with a brain disorder associated with a genetic or chromosomal abnormality. 
   
   
       12 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with a brain disorder associated with a genetic or chromosomal abnormality. 
   
   
       13 . The use of any of  claims 11 - 12 , wherein said chromosomal abnormality is a Down's syndrome. 
   
   
       14 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for ameliorating hippocampal-dependent memory loss in a subject, wherein said hippocampal-dependent memory loss is secondary to meningitis. 
   
   
       15 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for ameliorating hippocampal-dependent memory loss in a subject, wherein said hippocampal-dependent memory loss is secondary to meningitis. 
   
   
       16 . The use of any of  claims 14 - 15 , wherein said meningitis is secondary to an infectious agent. 
   
   
       17 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with a brain disorder associated with Lyme Disease. 
   
   
       18 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for improving hippocampal-dependent memory in a subject with a brain disorder associated with Lyme Disease. 
   
   
       19 . Use of uridine, an acyl derivative thereof, or a uridine phosphate in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of brain damage in a subject. 
   
   
       20 . Use of (a) uridine, an acyl derivative thereof, or a uridine phosphate; and (b) choline or an ester or salt thereof in the manufacture of a medicament, nutritional supplement, or composition for treating or reducing an incidence of brain damage in a subject. 
   
   
       21 . The use of any of  claims 1 - 20 , wherein said uridine phosphate is a uridine-5′-monophosphate (UMP), uridine-5′-diphosphate (UDP), uridine-5′-triphosphate (UTP), or is a salt of said UMP, UDP, or UTP. 
   
   
       22 . The method of any of  claims 1 - 21 , wherein said medicament, nutritional supplement, or composition is chronically administered. 
   
   
       23 . The method of any of  claims 1 - 22 , wherein said medicament, nutritional supplement, or composition is orally administered 
   
   
       24 . The method of any of  claims 2 ,  4 ,  6 ,  8 ,  10 ,  12 ,  15 ,  18 , or  20 - 23 , wherein said choline salt is choline chloride, choline bitartrate, or choline stearate. 
   
   
       25 . The method of any of  claims 1 - 24 , wherein said medicament, nutritional supplement, or composition contains 200 mg-1 g of uridine. 
   
   
       26 . The method of any of  claims 1 - 24 , wherein said medicament, nutritional supplement, or composition contains 300 mg-1.2 g of UMP. 
   
   
       27 . The method of any of  claims 1 - 26 , wherein said medicament, nutritional supplement, or composition contains 1-15 mg/kg choline or a molar equivalent thereof of a choline salt or choline ester.